Becton, Dickinson and Company
BDXHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science. At a $50.32B market cap, Becton, Dickinson and Company ranks as a large-cap company within healthcare. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Market Cap
$50.32B
Beta
0.28
P/E (TTM)
31.96
P/E (Fwd)
13.90
EPS (TTM)
$5.78
EPS (Fwd)
$13.29
ROE
6.6%
ROA
4.3%
Cash
$709.0M
Total Debt
$16.81B
Free CF
$4.48B
52W Change
22.7%
Annual Financials
Cash vs Debt
Where BDX stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, BDX finished 17.90% above its 150-day moving average ($159.55) and 19.18% above its 200-day moving average ($157.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDX overbought or oversold?
At the September 1, 2026 close, BDX's RSI(14) was 62.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Becton, Dickinson and Company carries $16.81B in total debt against $709.0M in cash reserves — debt is roughly 23.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $4.48B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 6.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $18.87B to $21.84B.
With a beta below 0.7, Becton, Dickinson and Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Becton, Dickinson and Company carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing BDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.